Mandate

Vinge advises Industrifonden in connection with the disposal of all shares in the children’s shoes company, Vincent

June 28, 2013

Vinge is advising Industrifonden in connection with the disposal of all shares in the children’s shoes company, Vincent Shoe Store AB, which designs and sells a complete collection of children’s shoes under its own trademark. The purchaser is Wonderful Times Group AB (publ), one of the Nordic region’s leading distributors of children’s products. Under the agreement, the acquisition will be effected through an issue in kind of 18 million shares in Wonderful Times, which is conditional upon an extraordinary general meeting adopting a resolution concerning the consideration shares. At present, Vincent Shoe Stores AB is primarily owned by Kattvik Financial Services AB and Industrifonden, which will acquire a significant holding in Wonderful Times as a result of the transaction.

Vinge’s team consisted of responsible partner Johan Larsson and associate Jonas Johansson.

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026